Infectious diseases prevalence, vaccination coverage, and diagnostic challenges in a population of internationally adopted children referred to a Tertiary Care Children's Hospital from 2009 to 2015.

Sara Sollai, Francesca Ghetti, Leila Bianchi, Maurizio de Martino, Luisa Galli, Elena Chiappini
Author Information
  1. Sara Sollai: Department of Health Sciences, University of Florence, Meyer Children's University Hospital, Florence, Italy.

Abstract

Infectious diseases are common in internationally adopted children (IAC).With the objective to evaluate infectious diseases prevalence in a large cohort of IAC and to explore possible risk factors for tuberculosis (TB) and parasitic infections, clinical and laboratory data at first screening visit of all IAC (<18 years) consecutively referred to our Center in 2009 to 2015 were collected and analyzed.In total, 1612 children (median age: 5.40 years; interquartile range: 3.00-7.90) were enrolled, 123/1612 (7.60%) having medical conditions included in the special needs definition. The most frequent cutaneous infections were Molluscum contagiosum (42/1612; 2.60%) and Tinea capitis (37/1612; 2.30%). Viral hepatitis prevalence was <1% (hepatitis B virus [HBV]: 13 children, 0.80%; hepatitis C virus: 1 child, 0.10%; hepatitis A virus: 6 children, 0.40%). A parasitic infection was diagnosed in 372/1612 (23.10%) children. No risk factors for parasitosis were evidenced. Active TB was diagnosed in 4/1355 (0.3%) children, latent TB in 222/1355 (16.40%). Only 3.7% (51/1355) children had concordant positive tuberculin skin test (TST) and QuantiFERON-TB-Gold In-Tube (QFT-G-IT) results. Risk factors for TST+/QFT-G-IT- results were previous Bacille de Calmette-Guérin vaccination (adjusted odds ratio [aOR]: 2.18; 96% confidence interval [CI]: 1.26-3.79; P = 0.006), and age ≥5 years (aOR: 1.49; 95% CI: 1.06-2.11; P = 0.02). The proportion of children with nonprotective titers for vaccine-preventable diseases (VPD) ranged from 15.70% (208/1323) for tetanus to 35.10% (469/1337) for HBV.Infectious diseases were commonly observed in our cohort. The high rate of discordant TST/QFT-G results brings up questions regarding the optimal management of these children, and suggests that, at least in children older than 5 years, only QFT-G-IT results may be reliable. The low proportion of children protected for VPD, confirms importance of a timely screening.

References

  1. Pediatrics. 2009 Jan;123(1):30-7 [PMID: 19117857]
  2. Pediatr Infect Dis J. 2015 Oct;34(10):1141-2 [PMID: 26367809]
  3. Pediatr Clin North Am. 2005 Oct;52(5):1287-309, vi [PMID: 16154464]
  4. Pediatr Nurs. 2008 Nov-Dec;34(6):480-5, 489 [PMID: 19263756]
  5. Pediatr Infect Dis J. 2009 Aug;28(8):669-73 [PMID: 19633512]
  6. Pediatr Infect Dis J. 2015 Jun;34(6):599-603 [PMID: 25973937]
  7. Pediatr Infect Dis J. 2016 Mar;35(3):231-6 [PMID: 26646547]
  8. J Ark Med Soc. 2009 Dec;106(7):137-9 [PMID: 20014518]
  9. Pathog Glob Health. 2012 Jul;106(3):172-6 [PMID: 23265375]
  10. Tuberculosis (Edinb). 2012 Nov;92(6):505-12 [PMID: 22877977]
  11. Pediatrics. 2001 Sep;108(3):608-12 [PMID: 11533325]
  12. Arch Dis Child. 2012 Jun;97(6):514-6 [PMID: 21543457]
  13. Pediatr Infect Dis J. 2015 Jan;34(1):35-9 [PMID: 25093974]
  14. Vaccine. 2010 Dec 10;29(1):95-103 [PMID: 21036132]
  15. J Microbiol Methods. 2013 Aug;94(2):133-134 [PMID: 23732753]
  16. Infection. 2001 Aug;29(4):188-91 [PMID: 11545477]
  17. Vaccine. 2006 May 8;24(19):4138-43 [PMID: 16545505]
  18. J Pediatric Infect Dis Soc. 2015 Jun;4(2):96-103 [PMID: 26407408]
  19. Am J Respir Crit Care Med. 2000 Apr;161(4 Pt 1):1376-95 [PMID: 10764337]
  20. Niger J Clin Pract. 2015 May-Jun;18(3):307-11 [PMID: 25772909]
  21. Acta Biomed. 2011 Dec;82(3):208-13 [PMID: 22783717]
  22. Curr Opin Pediatr. 2013 Feb;25(1):78-87 [PMID: 23295719]
  23. Pediatrics. 2011 Sep;128(3):e613-22 [PMID: 21824880]
  24. Thorax. 2002 Sep;57(9):804-9 [PMID: 12200526]
  25. Clin Microbiol Infect. 2014 Aug;20(8):746-51 [PMID: 24261464]
  26. J Travel Med. 2015 May-Jun;22(3):179-85 [PMID: 25787709]
  27. Minerva Pediatr. 2006 Feb;58(1):55-62 [PMID: 16541007]
  28. Diagn Microbiol Infect Dis. 2010 Apr;66(4):366-72 [PMID: 20071130]
  29. BMC Infect Dis. 2013 Jun 05;13:265 [PMID: 23738853]
  30. Semin Respir Crit Care Med. 2004 Jun;25(3):353-64 [PMID: 16088476]
  31. Pediatrics. 2005 Jun;115(6):e710-7 [PMID: 15930199]
  32. Eur J Pediatr. 2009 Sep;168(9):1101-6 [PMID: 19125292]
  33. Clin Infect Dis. 2005 Jan 15;40(2):286-93 [PMID: 15655749]
  34. Pharmacotherapy. 2006 Sep;26(9):1207-20 [PMID: 16945042]
  35. Pediatrics. 2010 Dec;126(6):e1522-9 [PMID: 21059723]
  36. MMWR Recomm Rep. 2010 Jun 25;59(RR-5):1-25 [PMID: 20577159]
  37. Pediatrics. 2008 Dec;122(6):1223-8 [PMID: 19047238]
  38. Indian J Med Res. 2009 Nov;130(5):646-50 [PMID: 20099404]
  39. Ugeskr Laeger. 2013 Jun 17;175(25):1789-93 [PMID: 23773218]
  40. Pediatr Infect Dis J. 2014 Dec;33(12):1291-3 [PMID: 25037039]
  41. Ugeskr Laeger. 2008 Apr 21;170(17):1468-72 [PMID: 18462628]
  42. Pediatr Clin North Am. 2005 Oct;52(5):1271-86, vi [PMID: 16154463]
  43. J Antimicrob Chemother. 2010 May;65(5):859-65 [PMID: 20233775]
  44. An Pediatr (Barc). 2015 May;82(5):302-7 [PMID: 25047307]
  45. Scand J Infect Dis. 2014 Sep;46(9):660-4 [PMID: 25073538]
  46. Clin Diagn Lab Immunol. 2005 Oct;12(10):1231-4 [PMID: 16210488]
  47. Pediatr Infect Dis J. 2011 Aug;30(8):694-700 [PMID: 21427627]
  48. Pediatrics. 2012 Jan;129(1):e214-23 [PMID: 22201151]
  49. Eur J Clin Microbiol Infect Dis. 2012 Apr;31(4):491-7 [PMID: 21744280]
  50. J Virol Methods. 2016 Nov;237:38-39 [PMID: 27575683]
  51. BMC Infect Dis. 2014;14 Suppl 1:S6 [PMID: 24564486]
  52. Pediatrics. 2000 Jun;105(6):E76 [PMID: 10835089]
  53. Ann Intern Med. 2003 Sep 2;139(5 Pt 1):371-8 [PMID: 12965946]
  54. Clin Microbiol Rev. 2005 Jul;18(3):510-20 [PMID: 16020687]
  55. Arch Pediatr. 1999 Oct;6(10):1053-8 [PMID: 10544779]
  56. Ann Ig. 2003 May-Jun;15(3):261-70 [PMID: 12910879]
  57. Int J Parasitol. 2015 Feb;45(2-3):133-40 [PMID: 25486494]
  58. Pediatr Clin North Am. 2013 Apr;60(2):487-505 [PMID: 23481113]
  59. APMIS. 2015 Aug;123(8):648-51 [PMID: 26140432]
  60. Vaccine. 2010 Nov 23;28(50):7947-55 [PMID: 20937322]

MeSH Term

Adoption
Age Factors
Child
Child, Preschool
Communicable Diseases
Children with Disabilities
Female
Hospitals, Pediatric
Humans
Internationality
Italy
Male
Prevalence
Prospective Studies
Risk Factors
Sex Factors
Tertiary Care Centers
Vaccination

Word Cloud

Created with Highcharts 10.0.0childrendiseasesyearshepatitis01resultsInfectiousIACprevalencefactorsTB210%internationallyadoptedcohortriskparasiticinfectionsscreeningreferred200920155360%virus:40%diagnosedQFT-G-ITvaccinationP = 0proportionVPDcommonWithobjectiveevaluateinfectiouslargeexplorepossibletuberculosisclinicallaboratorydatafirstvisit<18consecutivelyCentercollectedanalyzedIntotal1612medianage:40interquartilerange:00-790enrolled123/16127medicalconditionsincludedspecialneedsdefinitionfrequentcutaneousMolluscumcontagiosum42/1612Tineacapitis37/161230%Viral<1%Bvirus[HBV]:1380%Cchild6infection372/161223parasitosisevidencedActive4/13553%latent222/1355167%51/1355concordantpositivetuberculinskintestTSTQuantiFERON-TB-GoldIn-TubeRiskTST+/QFT-G-IT-previousBacilledeCalmette-Guérinadjustedoddsratio[aOR]:1896%confidenceinterval[CI]:26-379006age≥5aOR:4995%CI:06-21102nonprotectivetitersvaccine-preventableranged1570%208/1323tetanus35469/1337HBVcommonlyobservedhighratediscordantTST/QFT-GbringsquestionsregardingoptimalmanagementsuggestsleastoldermayreliablelowprotectedconfirmsimportancetimelycoveragediagnosticchallengespopulationTertiaryCareChildren'sHospital

Similar Articles

Cited By